Equillium (EQ) Revenue (2023 - 2024)
Equillium's (EQ) quarterly Revenue came in at $4.4 million in Q4 2024, down 52.32% year-on-year from $9.2 million in Q1 2024, and down 63.88% on a QoQ basis from $12.2 million in Q3 2024.
Equillium (EQ) Revenue (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of Revenue data on file, last reported at $4.4 million in Q4 2024.
- On a quarterly basis, Revenue fell 52.32% year-over-year to $4.4 million in Q4 2024; TTM through Sep 2025 was $4.4 million, a 90.43% decrease from a year earlier, with the FY2024 full-year figure at $41.1 million, up 13.89% from the prior year.
- Revenue for Q4 2024 stood at $4.4 million, down from $12.2 million in the prior quarter.
- Over the last five years, Revenue for EQ reached as high as $13.9 million in Q2 2024 and fell as low as $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 12.16 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 9.21 Mn |
| Sep 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 8.88 Mn |